“A pilot randomized study published in Translational Psychiatry (2023) found that in women with Major Depressive Disorder and symptoms of anxiety, taking 5 g of creatine per day was associated with a reduction in anxiety levels, including reduced anxiety within the first week, further improvement throughout the study, and a noticeable…”
Plain restatementA 2023 pilot randomized controlled trial in the journal Translational Psychiatry reported that 5 g/day of creatine reduced anxiety in women with MDD, with effects appearing in week one and progressive improvement thereafter.
The post cites a 2023 pilot randomized study in *Translational Psychiatry* showing 5 g of creatine per day reduced anxiety in women with major depressive disorder. No such study could be found. The description most closely matches an older 2015 pilot by Hellem and colleagues in the *Journal of Dual Diagnosis*, which was an open-label trial (not randomized) in 14 women with depression and methamphetamine dependence, and which reported anxiety reductions starting at week 2, not week 1. The general idea that small studies suggest creatine may improve mood and anxiety symptoms is supported by the literature, but the specific citation and several details in the post are inaccurate. Creatine's role in brain energy metabolism is real, but current evidence for treating anxiety in humans remains preliminary and comes from very small trials. Anyone considering creatine for mental health should not rely on this post's specific citation and should consult a healthcare professional.
A pilot randomized [drifted from the evidence:] study published in Translational Psychiatry [drifted from the evidence:] (2023) found that [drifted from the evidence:] in women with Major Depressive Disorder and symptoms of anxiety, taking 5 [drifted from the evidence:] g of creatine [drifted from the evidence:] per day was associated with a reduction in anxiety levels, including reduced anxiety [drifted from the evidence:] within the first week, [drifted from the evidence:] further improvement throughout the study, and [drifted from the evidence:] a noticeable reduction in scores on clinical anxiety scales.
A [added by the neutral restatement:] 2023 pilot randomized [added by the neutral restatement:] controlled trial in [added by the neutral restatement:] the journal Translational Psychiatry [added by the neutral restatement:] reported that 5 [added by the neutral restatement:] g/day of creatine reduced anxiety [added by the neutral restatement:] in women with MDD, with effects appearing in week [added by the neutral restatement:] one and [added by the neutral restatement:] progressive improvement thereafter.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- A real pilot study did test 5 g/day creatine in a small group of women and reported reductions in both depression and anxiety scores that were maintained through the study.
- Creatine is involved in brain energy metabolism and ATP availability; this is uncontroversial background biology.
- There is a broader and growing (but still preliminary) research literature on creatine and mental health.
- The disclaimers in the post (small sample size, need for larger trials, not a replacement for medical treatment) are accurate.
- **Fabricated / mismatched source attribution:** The post cites "Translational Psychiatry (2023)." No such 2023 pilot RCT on creatine for anxiety in women with MDD exists in that journal based on the searches conducted. This is a source/date mismatch.
- **Study design mislabeled:** The most likely underlying study (Hellem 2015) was **open-label**, not "randomized." Randomized trials in this area (e.g., Lyoo 2012) targeted depression, not anxiety, and did not report the described anxiety-specific timeline.
- **Timeline overstated:** The claim says "reduced anxiety within the first week." The Hellem study reports significance beginning at week 2. This is a temporal exaggeration.
- **Population generalized:** Participants were women with methamphetamine dependence and comorbid depression, a very specific clinical group. The post reframes this as "women with MDD and symptoms of anxiety," which suggests a broader, cleaner population than was studied.
- Whether the post is referencing a study the investigator could not locate. Searches across PubMed, Nature/*Translational Psychiatry*, and general engines returned no match for the exact attribution.
- Whether the poster conflated multiple studies (e.g., Hellem 2015 for the anxiety finding, and a different *Translational Psychiatry* creatine paper for the citation). ---
The description in the post most closely matches the Hellem et al. 2015 pilot in the *Journal of Dual Diagnosis*, not a 2023 *Translational Psychiatry* paper. Fourteen females with depression and comorbid methamphetamine dependence were enrolled in an 8-week open label trial of 5 grams of daily creatine monohydrate; of these 14, eleven females completed the study. The results of a linear mixed effects repeated measures model showed significantly reduced HAMD and BAI scores as early as week 2 when compared to baseline scores. This improvement was maintained through study completion. An earlier randomized controlled trial in women with MDD (Lyoo et al. 2012, *American Journal of Psychiatry*) used 5 g/day of creatine augmenting escitalopram, but its primary outcome was depression (HAM-D), not anxiety, and it was not published in *Translational Psychiatry*. The only prominent *Translational Psychiatry* paper on creatine and mood in the relevant time window is a 2020 dietary-intake observational study, not a pilot RCT on supplementation. ---
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/72ea51d337c1/FHx5C7ic-t7Qc-TTDa4CHeD
Ask this case
Answers come only from the case file above; nothing is added.
Does the 2023 Translational Psychiatry study cited in the post actually exist?
No matching study was found. Searches of PubMed and the journal itself returned no 2023 pilot randomized controlled trial on creatine for anxiety in women with major depressive disorder published in Translational Psychiatry.
What real study does the claim most closely resemble?
It most closely matches a 2015 open-label pilot by Hellem and colleagues, published in the Journal of Dual Diagnosis, which gave 5 g of creatine daily to 14 women with depression and methamphetamine dependence and found reductions in both depression and anxiety scores.
Was the underlying study actually randomized, as the post states?
No. The Hellem 2015 study, which best fits the description, was open-label, meaning participants knew they were receiving creatine and there was no control group.
Did anxiety improve in the first week, as the post claims?
No. The Hellem study found statistically significant reductions in anxiety scores beginning at week 2, not week 1.
Is the general idea that creatine may help with mood and anxiety supported by research?
There is a small and growing body of research suggesting creatine may have benefits for mood symptoms, but the investigation found that current evidence comes from very small, preliminary trials and does not support the specific claims made in the post.